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Objectives: Sepsis is a complex clinical problem that is caused by excessive secretion of proinﬂammatory
and inﬂammatory mediators; these factors can result in pathophysiological hematological abnormalities
and multiple organ failure. To date, long-term investigations into septic pathophysiology and treatment
remain a major challenge. The aim of this study was to assess possible role of activating transcription
factor 3 (ATF3) in lipopolysaccharide (LPS)-induced acute liver inﬂammation and mortality in mice.
Materials and Methods: ATF3-deﬁcient (knock out, KO) mice and wild type (WT) mice were injected with
LPS to induce endotoxemia and scored for their survival rate. Automaticmultiparameter blood cell counting
was used for white blood cell (WBC) analysis, and liver histology was evaluated for acute hepatic injury.
Results: At 3 to 6 hours after LPS (50 mg/kg, intraperitoneally) challenge, AFT3-KO mice were found to
show a signiﬁcant elevation in circulating WBCs. This was accompanied by persistent elevation of WBCs
at 24 hours after LPS challenge compared to WT mice. The histopathological changes to the livers of the
ATF3-KO mice after LPS challenge consisted of prominent inﬂammation with more severe structural
disruption compared to WT mice. The above ﬁndings are in agreement with the decreased survival rate
of AFT3-deﬁciency mice after LPS challenge compared to WT mice.
Conclusion: We demonstrated the beneﬁcial role of ATF3 during LPS-induced endotoxemia in mice. ATF3
would seem to be a potential therapy regimen when treating LPS-induced endotoxemia.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Sepsis is a serious clinical problem worldwide and its incidence
and mortality rates remain high. In addition, severe sepsis is the
most common cause of mortality in intensive care units [1]. The
sepsis syndrome is a systemic inﬂammatory response caused by
excessive secretion of proinﬂammatory mediators that results in
hypotension, hematological abnormalities, and multiple organ
failure [2]. Multiple organ dysfunction is the most critical deter-
minant of prognosis in endotoxemia and sepsis [3]. Early organ
dysfunction in sepsis is a result of cellular activation by bacterialResearch, Buddhist Tzu Chi
ualien, Taiwan. Tel.: þ886 3
Cheng).
ddhist Compassion Relief Tzu Chiproducts such as lipopolysaccharide (LPS), the complex interaction
of inﬂammatory cytokines and the presence of hemodynamic
abnormalities that causes reduced oxygen delivery. Early organ
dysfunction due to sepsis is generally not related to cell death.
Many studies have indicated that cells undergo a metabolic shut-
down to protect against tissue injury in response to the early
phases of infection and sepsis [4]. High levels of reactive oxygen
species can occur during early sepsis and these damage mito-
chondria and other organelles [5]. Human hepatocytes have
abundant mitochondria and as a result it is reasonable that, during
sepsis, liver injury occurs before lung or heart injury. Successful
management of sepsis needs therapies that disrupt the key path-
ways of sepsis. However, controversy remains concerning the
relative roles of the various pathways involved in sepsis.
Toll-like receptors (TLRs) are membrane-bound pattern recog-
nition receptors that detect a variety of microbial speciﬁc motifs inFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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a major outer membrane component of Gram-negative bacteria
and does this in cooperation with its co-receptor MD2 [5]. The
binding of LPS to TLR4-MD2 leads to activation of various down-
stream signaling pathways [6]. In macrophages, activating tran-
scription factor 3 (ATF3) has been shown to be induced by the TLR4
ligand, LPS, using human peripheral blood mononuclear cells [7].
ATF3 belongs to the ATF/cAMP responsive element-binding protein
family of transcription factors. Previous studies have revealed a role
for ATF3 in various negative feedback mechanisms that control
immune cell activation including in macrophages [8]. In macro-
phages, ATF3 has been demonstrated to participate in the negative
feedback loop that modulates TLR4-stimulated inﬂammatory
responses as previously mentioned [9]. The proof that ATF3 nega-
tively regulates the transcription of nuclear factor (NF)-kB-depen-
dent genes was provided many years ago [10]. Recently it has been
suggested that ATF3 contributes to the negative regulation of
inﬂammatory cytokine gene expression by recruiting histone
deacetylase-1 to ATF/NF-kB binding sites in order to curtail the
production of inﬂammatory cytokine genes and that this prevents
damaging inﬂammatory responses after acute kidney injury [11].
Promising ﬁndings have also suggested that the TLR and ATF3
pathways act as host defense mechanisms against invading path-
ogens. Indeed, TLRs are able to activate various complicated cellular
signaling pathways that induce antiviral and antibacterial reactions
[12]. ATF3 may suppress the later phases (>16 hours) of TLR-
stimulated IL-6 production in response to LPS treatment [9].
ATF3-deﬁcient (knockout, KO) mice have recently been reported to
exhibit better protection against murine cytomegalovirus infection
[13] and to show moderate hyper-responsiveness to asthma and
airway inﬂammation. Thus, ATF3 would seem to mediate inﬂam-
matory responses by restricting the expression of different cyto-
kines in a number of biologically relevant diseasemodels. Given the
evidence that LPS signiﬁcantly elevates ATF3 protein expression in
macrophages, and that ATF3 is a negative transcriptional regulator
of TLR-mediated cytokine expression, it may be postulated that
ATF3 acts as a crucial regulator of immunity against invading
pathogens and inﬂammatory diseases.
ATF3-KO mice show no developmental deformities and mani-
fest phenotypes only when facedwith stressors [14]. ATF3-KOmice,
when challenged with intraperitoneal (ip) LPS, show a considerably
raised morbidity and mortality due to their increased susceptibility
to endotoxic shock as compared to wild type controls (data not
show). In this study, we have demonstrated the beneﬁcial effects of
ATF3 on the LPS-induced endotoxemic mortality and acute liver
inﬂammation in mice. ATF3 maintains the circulating WBC balance
and protects against hepatic injury. We also explored how ATF3
affects the survival rate of mice after LPS challenge. It can be
concluded that ATF3 exerts a beneﬁcial effect in terms of mortality
and its presence helps to limit liver dysfunction during sepsis.2. Materials and methods
2.1. Animals
Eight-week-old male mice weighing 20 to 25 g were bred and
housed under a 12-hour light/dark cycle at Tzu Chi University’s
Animal Center. The ATF3-KO mice were kindly provided by Dr.
Tsonwin Hai. C57BL/6J (B6) mice (age 8 to 12 weeks) were
purchased from Lasco Laboratories (Taipei, Taiwan) and provided
by Professor Sung-Ho Chen (Tzu Chi University, Hualien, Taiwan).
Food and water were provided ad libitum. All experimental proce-
dures and protocols were approved by the Animal Care and Use
Committee of the University of Tzu Chi and all animal care andexperiments were performed according to the Guide for the Care
and Use of Laboratory Animals (NRC, USA, 1996).
2.2. Mouse model for endotoxemia
In order to evaluate the beneﬁcial effects of ATF3 in terms of
sepsis-related liver injuries, animals were divided randomly into
four groups: Groups 1 and 2 (Control): wild type (WT) mice and
ATF3-KO mice, respectively, which received an ip injection of
normal saline as solvent; and Groups 3 and 4 (LPS): WT mice and
ATF3-KO mice, respectively, that received ip LPS (50 mg/kg) in
normal saline. Each group was subdivided into four subgroups
(n¼ 4) and these subgroups were observed and examined at 0, 3, 6,
12, and 24 hours after LPS challenge. Blood (0.5 mL) was sampled
from the right atrium, transferred to 1.6 mL tubes, centrifuged at
8000g at 4 C for 10 minutes and the plasma samples were frozen
at80 C for further analysis. The livers of the mice were harvested
from the animals sacriﬁced at 24 hours after LPS challenge and
these were then studied further.
2.3. Whole blood WBC and LYM measurement
Immediately after the drawing of the whole blood samples
(100 mL), these were analyzed on an automatic multi-parameter
blood cell counter (KX-21; Sysmex, Kobe, Japan).
2.4. Histopathology
Liver specimens were ﬁxed in 4% paraformaldehyde (pH 7.6;
Sigma Chemicals, St Louis, MO, USA) overnight at room tempera-
ture. After washing with tap water for 10 minutes, specimens were
dehydrated through a graded ethanol series (75% for 30 minutes,
80% for 60 minutes, 95% for 3 hour, and 100% for 30 minutes,
purchased from Sigma Chemicals) and then embedded in parafﬁn.
Sections of 1-mm thickness were placed on glass slides and dried at
37 C for overnight. The slides were then rinsed in nonxylene
solution (three times for 5 minutes each time) to remove the
parafﬁn. After rehydration (ethanol at 100% twice for 3 minutes, at
95% for 1 minute, and at 75% for 1 minute), the specimens were
processed in hematoxylin for 3 minutes, and then stained with
eosin Y for 45 seconds. All sections were then incubated in non-
xylene solution (Sigma Chemicals) for 6 minutes. After mounting
with a cover slip, each of the specimens was examined under a light
microscope (Leica Microsystems, Wetzlar, Germany).
2.5. Measurement of mice survival rate
WT and ATF3-deﬁciency mice were used to evaluate survival
rate. Using an in vivo endotoxemic model, the mice received doses
of LPS ip that should be lethal to approximately 80% of the animals
tested (LD80 dose). The mice were randomly divided into four
groups as described above. After solvent (n¼ 8) or LPS (n¼ 20)
challenge, the survival rate of each group was calculated at 0, 3, 6,
12, and 24 hours.
2.6. Drugs
Sodium chloride, E coli LPS (serotype 0127:B8), and Tween 80
were purchased from Sigma Chemicals. E coli LPS was diluted in
normal saline to a concentration of 10 mg/ml before use.
2.7. Statistical analysis
Experimental data are presented as means SEM. One-way
ANOVA was used to determine any signiﬁcant differences.
Fig. 1. Effects of ATF3 deﬁciency in mice on LPS-induced changes in physiological
parameters after LPS challenge. Change in the physiological parameters of white blood
cells (WBCs) in whole blood at 0, 3, 6, and 24 h for various different groups of wild-
type or ATF3-deﬁcient mice that received an injection of control saline or LPS saline
(50 mg/kg, ip). The data represent means. *p< 0.05 indicates a signiﬁcant difference
from the respective control, and #&xp< 0.05 indicates a signiﬁcantly different from the
respective LPS-treated group.
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unpaired t test. A p value< 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Changes in physiological parameter upon LPS challenge in mice
Any changes in circulatory parameter WBC number during the
mice model of LPS-induced endotoxemia were assessed at 0, 3, 6,Fig. 2. ATF3 prevented LPS-induced severe liver injury in mice. Representative sections of liv
obtained using the mice model of endotoxemia. The control section shows a normal centr
when the liver was examined at 24 h after LPS challenge (ip, 50 mg/kg), structural disruptio
macrophages (arrows) with PMNs can be seen to have accumulated near the central vein.and 24 hours. In the ATF3-KO mice, circulating WBC numbers were
enhanced at 3 hours after LPS challenge and reached a maximum 6
hours after LPS challenge (Fig. 1). WBC numbers remained
substantially increased until 24 hours (Fig. 1). However, when WT
mice were investigated, although there as a signiﬁcant increase in
WBC numbers at 3 hours after LPS challenge, it was found that this
initial increase in wild-type circulating WBC levels had already
begun to decrease at 6 hours after LPS challenge (Fig. 1). These
results indicate that during the early and later stages of inﬂam-
mation, ATF3 helps to reduce the LPS-induced increase in WBC
numbers (Fig. 1).
3.2. ATF3 prevents LPS-induced endotoxemic liver injury
To evaluate the therapeutic relevance of these ﬁndings, we
examined the pathological changes to the liver caused by LPS
administration and whether ATF3 prevents LPS-induced endo-
toxemic liver injury. Generally, near the central vein, the duct
became ﬁlled with polymorphonuclear neutrophils (PMNs), and
was found to have an abnormal structure at 24 hour after LPS
challenge (Fig. 2). However, in the ATF3-KO mice, it was found that
there was an accumulation of macrophages such as Kupffer cells
and that there was PMN sequestration within the liver. In general,
the severity of the liver damage among the ATF3-deﬁcient mice
after LPS challenge was much greater than that found in wild type
mice after LPS challenge (Fig. 2).
3.3. ATF3 improves the survival rate of LPS-induced endotoxemic
mice
Overall, 10% of ATF3-deﬁcient mice that were injected with ip
50 mg/kg LPS survived until 24 hours (Fig. 3). However, the wild-
type mice showed a statistically signiﬁcant improvement in theer tissues stained with hematoxylin for cell nucleus, and eosin Y dye for the cytoplasm
al vein, normal liver structure, and few neutrophils. However, in ATF3-deﬁcient mice,
n and ﬁlling of the ducts with numerous neutrophils can be seen. Numerous activated
Fig. 3. ATF3 increases mice survival rate after LPS-induced endotoxemia. After intra-
peritoneal (ip) treatment with 50 mg/kg, it was found that wild-type mice showed
a signiﬁcant and time-depend increase in survival rate compared to ATF3-deﬁcient
mice. This suggests that ATF3 has a beneﬁcial effect on survival during endotoxemia.
#p< 0.05, signiﬁcantly different from the LPS-treated group. n indicates the number of
experiments.
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after LPS challenge (Fig. 3). These results support the hypothesis
that ATF3 provides a survival advantage in the presence of LPS-
induced endotoxemia.
4. Discussion
Sepsis is frequently fatal and has been found to kill 20% to 50% of
severely affected patients in the United States [15]. Moreover, sepsis
signiﬁcantly lowers the quality of life of those who survive [16].
Gram-negative bacteria are the group of major pathogens causing
sepsis [17]. For this reason, we chose LPS to induce endotoxemia in
the mice. The chance of organ failure increases over time and is an
additive contributor to mortality; this remains consistent across
patients of different races and sexes [17]. The pathophysiology of
sepsis is supposed to be associated with a devastating or excessive
host response involving dysregulated inﬂammation. Septic shock
induced organ hypoperfusion, which progresses to multiple organ
dysfunction; this is clinically characterized by liver, pulmonary,
cardiovascular, renal, and gastrointestinal dysfunction [18].
According to Consensus Deﬁnition of SIRS/Sepsis by the Amer-
ican College of Chest Physicians and the Society of Critical Care
Medicine [19], systemic inﬂammatory response syndrome can be
seen following awide variety of insults and occurs whenmore than
one of the following clinical signs are present: (1) a body temper-
ature >38 C or <36 C; (2) a heart rate >90 beats/minute; (3)
tachypnea, manifested by a respiratory rate>20 breaths/minute, or
hyperventilation, as indicated by a PaCO2 of >32 mmHg; and (4)
a change in theWBC count, such as a count>12109/L, a count less
than 4109/L, or the existence of more than 10% immature
neutrophils (“bands”). A change in WBC count is likely to be an
early identiﬁcation of an inﬂammatory response to an infection. In
our study, after LPS challenge, ATF3 deﬁcient mice showed a pro-
longed elevation of theirWBC count compared to theWTmice. This
implies that ATF3 is able to suppress SIRS during the early phase of
endotoxemia. The result corresponded with research last year
showing that, during sepsis, high ATF3 is found in patients who are
admitted to an intensive care unit [20].
Sepsis represents a systemic inﬂammatory response accompa-
nied byan infection. Severe sepsis is deﬁned as sepsis combinedwith
organ dysfunction. Retrospective clinical studies have noted that the
main risk to survival isnot theunderlyingdisease, orevenaparticular
complication, but is rather the development of progressive failureacross several interdependent organ systems [21]. Acute or chronic
liver failure and severe sepsis show a parallel degree of cellular
immune depression [22]. However, there remains an inadequate
pathophysiological basis for this conclusion and inclusion of sepsis as
a precipitating episode to acute liver failure remains questionable
[23]. Having examined the liver’s response to sepsis, the present
study found that ATF3-deﬁciency worsens LPS-induced liver injury
(Fig. 2). Among the nonsurvivors with liver failure, High mobility
group box 1 (HMGB-1) levels have been found to be much higher
than among survivors [18] and HMGB-1 level increased with the
number of organ failures. HMGB-1 has recently been identiﬁed as
a cytokine mediator of lethal systemic inﬂammation [24]. Heme
oxygenase-1 (HO-1) is important in the liver and other organs and is
required to restore cellular homeostasis in response to infection and
sepsis [25]. Thus, additional studies are required to address whether
there is a crosstalk between ATF3 and HMGB-1 and/or HO-1, and
whether this is a factor in the pathogenic progression of the
inﬂammatory disorders that lead to liver failure.
In addition to protecting against liver injury in a septic animal
model, our ﬁndings also demonstrated that ATF3 is capable of
improving the survival of endotoxemic mice (Fig. 3). Therefore, it
seems likely that ATF3 participates in a protective molecular
pathway during sepsis. Understanding this role has important
implications in relation to the pathophysiology of sepsis and
further advances in this area may help to diminish morbidity and
mortality due to sepsis.References
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